Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Entry inhibitors

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    255 result(s) found for: Entry inhibitors. Displaying page 5 of 13.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2004-001778-21 Sponsor Protocol Number: A4001028 Start Date*: 2005-02-02
    Sponsor Name:PFIZER LTD
    Full Title: A multicentre, randomised, double-blind, placebo-controlled trial of a novel CCR5 antagonist, UK-427,857 in combination with optimised background therapy versus optimised background therapy alone f...
    Medical condition: UK-427,857 is an antagonist of the human chemokine receptor, and is intended to help prevent the development and progression of AIDS in indivuduals HIV-1 positive.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004112-51 Sponsor Protocol Number: V1512-2PD01 Start Date*: 2006-11-14
    Sponsor Name:VERNALIS DEVELOPMENT LIMITED
    Full Title: A randomised, double-blind, double-dummy, two-period, cross-over study to determine the pharmacokinetics, pharmacodynamics and safety of multiple doses of V1512 effervescent tablets in Parkinson s ...
    Medical condition: Parkinson s disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-005000-26 Sponsor Protocol Number: 4658-us-201 Start Date*: 2017-03-16
    Sponsor Name:Sarepta Therapeutics, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Efficacy, Safety, Tolerability, and Pharmacokinetics Study of AVI-4658 (Eteplirsen), a Phosphorodiamidate Morpholino Oligomer, Administ...
    Medical condition: Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
    Disease: Version SOC Term Classification Code Term Level
    19.1 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Under 18 Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-004562-40 Sponsor Protocol Number: GOG-0146Q Start Date*: 2008-01-14
    Sponsor Name:Gynecologic Oncology Group
    Full Title: A PHASE II EVALUATION OF TOPOTECAN ADMINISTERED WEEKLY IN THE TREATMENT OF RECURRENT PLATINUM-SENSITIVE OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER
    Medical condition: Patients with recurrent ovarian, fallopian tube, or primary peritoneal cancers.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066697 Ovarian cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003847-66 Sponsor Protocol Number: H6Q-MC-S061 Start Date*: 2008-03-28
    Sponsor Name:Eli Lilly and company
    Full Title: Dose Finding and Randomized, Multicenter, Placebo-Controlled, Phase 2 Study of Enzastaurin and Sunitinib versus Placebo and Sunitinib in Patients with Metastatic Renal Cell Carcinoma
    Medical condition: Renal cell carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) AT (Completed) PL (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-019817-20 Sponsor Protocol Number: Start Date*: 2010-11-15
    Sponsor Name:Institut Bergonié
    Full Title: A phase II study of GDC-0449 in patients with advanced chondrosarcomas.
    Medical condition: Adult patients with unresectable locally advanced or metastatic chondrosarcomas.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10008736 Chondrosarcoma metastatic LLT
    Population Age: Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003307-21 Sponsor Protocol Number: 848016005-02 Start Date*: 2018-05-30
    Sponsor Name:Maastricht University
    Full Title: Tailored treatment of functional dyspepsia with nortriptyline: a multi-center double-blind placebo-controlled trial (TENDER)
    Medical condition: Functional dyspepsia (FD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-000050-38 Sponsor Protocol Number: CAIN457F2342 Start Date*: 2015-07-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase III, randomized, double-blind, placebo controlled multi-center study of subcutaneous secukinumab (150 mg and 300 mg) in prefilled syringe to demonstrate efficacy (including inhibition of st...
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) IE (Completed) HU (Completed) NL (Completed) ES (Completed) DE (Completed) IT (Completed) AT (Completed) LV (Completed) DK (Completed) CZ (Completed) FI (Completed) EE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2013-000965-34 Sponsor Protocol Number: E5501-G000-310 Start Date*: 2014-05-27
    Sponsor Name:Eisai Limited
    Full Title: A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia ...
    Medical condition: Thrombocytopenia in Patients with Chronic Liver Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10005329 - Blood and lymphatic system disorders 10035534 Platelet disorders HLGT
    18.0 10005329 - Blood and lymphatic system disorders 10043554 Thrombocytopenia PT
    18.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    18.0 10005329 - Blood and lymphatic system disorders 10039884 Secondary thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) IT (Completed) GB (Completed) AT (Completed) HU (Completed) ES (Completed) PT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-002620-17 Sponsor Protocol Number: 18-513 Start Date*: 2019-01-08
    Sponsor Name:Portola Pharmaceuticals, Inc
    Full Title: A PHASE 4 RANDOMIZED CLINICAL TRIAL OF ANDEXANET ALFA [ANDEXANET ALFA FOR INJECTION] IN ACUTE INTRACRANIAL HEMORRHAGE IN PATIENTS RECEIVING AN ORAL FACTOR XA INHIBITOR
    Medical condition: Oral FXa inhibitor-treated patients with acute intracranial bleeding.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10075279 Anticoagulant reversal therapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) BE (Completed) NL (Completed) ES (Prematurely Ended) GR (Completed) CZ (Completed) LV (Completed) FI (Prematurely Ended) NO (Prematurely Ended) LT (Prematurely Ended) PL (Completed) PT (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002571-34 Sponsor Protocol Number: CBKM120F2303 Start Date*: 2012-08-10
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase III randomized, double blind, placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative AI treated, locally advanced or metas...
    Medical condition: This study will evaluate whether the addition of daily BKM120 to fulvestrant is effective and safe in treating patients with hormone receptor-positive HER2 negative locally advanced or metastatic b...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) NO (Prematurely Ended) IT (Prematurely Ended) SE (Temporarily Halted) NL (Prematurely Ended) GR (Temporarily Halted) FI (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) BE (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004851-28 Sponsor Protocol Number: EVG001BC Start Date*: 2016-12-07
    Sponsor Name:Evgen Pharma PLC
    Full Title: A Multicentre Phase 2 Study of SFX-01 Treatment and Evaluation in Patients with Estrogen Receptor (ER) Positive and Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer...
    Medical condition: Estrogen Receptor (ER) Positive and Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer Progressing on either an Aromatase Inhibitor (AI) or Tamoxifen or Fulvestrant
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-001885-27 Sponsor Protocol Number: B7841002 Start Date*: 2017-05-09
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A MULTICENTER, OPEN-LABEL, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF SUBCUTANEOUS OR INTRAVENOUS PF-06741086 IN SUBJECT...
    Medical condition: Severe hemophilia A or B, with or without inhibitors to Factor VIII (FVIII) or Factor IX (FIX).
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10053754 Hemophilia B without inhibitors LLT
    20.0 100000004850 10053751 Hemophilia A with anti factor VIII LLT
    20.0 100000004850 10053753 Hemophilia A without inhibitors LLT
    20.0 100000004850 10053752 Hemophilia B with anti factor IX LLT
    Population Age: Adults Gender: Male
    Trial protocol: PL (Completed) ES (Completed) FR (Completed) BG (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2018-002990-24 Sponsor Protocol Number: RAD1901-308 Start Date*: 2019-05-29
    Sponsor Name:Stemline Therapeutics, Inc.
    Full Title: Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients with ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active-Control...
    Medical condition: Advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Ongoing) HU (Completed) AT (Completed) GR (Completed) IE (Completed) PT (Completed) DK (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000440-22 Sponsor Protocol Number: EURO-SKI01 Start Date*: 2012-04-11
    Sponsor Name:University of Heidelberg
    Full Title: MULTICENTER TRIAL ESTIMATING THE PERSISTANCE OF MOLECULAR REMISSION IN CHRONIC MYELOID LEUKAEMIA AFTER STOPPING TKI
    Medical condition: Patients with chronic myeloid leukemia with complete molecular response can stop tyrosine kinase inhibitors under close monitoring
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10009016 Chronic myeloid leukemia in remission LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing) FI (Completed) CZ (Completed) NL (Ongoing) NO (Completed) PT (Completed) AT (Prematurely Ended) ES (Ongoing) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001617-12 Sponsor Protocol Number: AP24534-14-203 Start Date*: 2017-10-09
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
    Medical condition: Chronic Phase Chronic Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10054352 Chronic phase chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) DE (Completed) FI (Prematurely Ended) ES (Completed) DK (Completed) NO (Completed) BE (Completed) FR (Trial now transitioned) NL (Completed) PT (Completed) PL (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004034-29 Sponsor Protocol Number: A206T-G01-001 Start Date*: 2018-12-19
    Sponsor Name:Advanced Accelerator Applications International SA
    Full Title: A Phase I/II open-label, multi-center, dose-escalation study of safety, tolerability, pharmacokinetics, dosimetry, and response to repeat dosing of 177Lu-PSMA-R2 radio-ligand therapy in patients wi...
    Medical condition: Patients with PSMA positive Metastatic Castration-resistant Prostate Cancer (mCRPC), and disease progression following previous systemic treatment for mCRPC.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10036908 Prostatic neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000501-52 Sponsor Protocol Number: PARAGON2011 Start Date*: 2011-12-07
    Sponsor Name:Greater Glasgow and Clyde [...]
    1. Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms
    Medical condition: Patients with potentially hormone responsive recurrent or metastatic gynaecological cancers from following subgroups: A - Epithelial ovarian cancer, primary peritoneal cancers and cancers of the fa...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026310 Malignant neoplasm of ovary LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014760 Endometrial neoplasm malignant LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-002510-38 Sponsor Protocol Number: D3569C00007 Start Date*: 2005-12-19
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, 52-Week, Parallel-Group, Multicentre, Phase IIb Study to Evaluate the Effects of Rosuvastatin 10 mg, Rosuvastatin 40 mg and Atorvastatin 80 mg on Urinary Protein Excreti...
    Medical condition: Male and female patients aged >= 18 and <=70 years with Type 1 or 2 diabetes, moderate proteinuria (baseline urinary protein/creatinine ratio >=500 mg/g and <=5000 mg/g), mild hypercholesterolaemia...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001286-20 Sponsor Protocol Number: CABL001I12201 Start Date*: 2021-07-29
    Sponsor Name:Novartis Pharma AG
    Full Title: A multi-center, open-label study to determine the dose and safety of oral asciminib in pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP...
    Medical condition: Pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10054352 Chronic phase chronic myeloid leukemia LLT
    21.0 100000004864 10060498 Juvenile chronic myeloid leukemia LLT
    24.0 100000004864 10082178 Philadelphia positive chronic myeloid leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 02:48:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA